Cancer vaccines have undergone a remarkable investigation over recent decades as an immunotherapeutic strategy designed to induce new or reinforce existing cytotoxic CD8 T cell lymphocyte (CTL) responses specific to tumor antigens [1,2]. Here, CD8A is linked to neoplasm.